Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is huge. In the major category of asthma drugs, leukotriene receptor antagonists have the fastest growing market share.

key word:

category therapeutic

Category:

API

Consulting
Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry finance platform company integrating pharmaceutical, intelligent medical, bio pharmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination reaction, bromination reaction, diazotization reaction, format reaction, etc.

Anti-asthmatic drugs

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is huge. In the major category of asthma drugs, leukotriene receptor antagonists have the fastest growing market share.

The main ingredient of this product is Prenast semi-hydrate, its chemical name is: 4-oxygen-8 -[4-(4-phenylbutaxy) -benzamide]-2-(5-tetrazolium) -4H-1-benzopyran semi-hydrate.

Molecular formula: C27H23N5O4·1/2H2O Molecular weight: 490.51

It is a respiratory antiasthmatic agent for the treatment of bronchial asthma. It is a leukotriene receptor antagonist. Mainly for prescription capsule.

Usage and dosage: Take 450mg(4 capsules) twice a day for adults, orally after breakfast and dinner. It can be increased or decreased according to age and symptoms. Adverse reactions are rare, generally below 0.1% ~ 5%.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics of this drug are that it can stimulate insulin secretion while reducing hunger without causing weight gain. Hypoglycemia and edema will not occur, and it is suitable for diabetic patients with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-oriented and realizes industrial development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for the treatment of arthritis. It is well tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In clinical application, it has good therapeutic effect on atopic asthma and other types of bronchial asthma, and the market prospect is huge. In the major category of asthma drugs, leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-oriented and realizes industrial development through R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA for Alzheimer's disease in the United States. Its treatment reaches the target dose and has low toxic and side effects. It has been widely recognized by our medical community, and good tolerance is its biggest advantage. In October 1999, Donepezil was launched in China under the trade name "Aricept", which is the main chemical drug against Alzheimer's disease. At present, CFDA has approved a number of domestic enterprises to produce donepezil preparations, the main dosage forms are tablets, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member states. The world's first drug approved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. From June 2019 to June 2020, the annual sales of apixaban products overseas reached about $15.4 billion, with a year-on-year growth of nearly 32%, and the API consumption reached about 23,960 kg, with a year-on-year growth of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-oriented and realizes industrial development through R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-oriented and realizes industrial development through R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-mail: 2880705932@qq.com
Submit
Union Pharmaceuticals

Follow WeChat

Anhui Union Pharmaceuticals Technology Co., Ltd.

Service line:

+86-21-54285906
E-mail：2880705932@qq.com
Add：4th Floor, Building B3, Creative Industry Park, Hefei, Anhui P.  R. China.

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.

Powered by www.300.cn  | SEO